PFF Help Center(844) 825-5733

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Artesunate

Status:

Phase 1

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Oral Drug

Funder Type:

Organization | University

Drug Details

Artesunate stops fibroblast-to-myofibroblast transition, reduces inflammatory signals like TGF-β1/Notch/STAT3, inhibits cell proliferation (p53/p21), decreases collagen deposition, and can induce cell death (ferroptosis/apoptosis) in pro-fibrotic cells, ultimately preventing scarring and improving lung function.

This study is a single-center, double-blind, placebo-controlled, randomized phase 1 study on the safety and efficacy of artesunate in participants with idiopathic pulmonary fibrosis (IPF).

Find a clinical trial